Silence Therapeutics plc (NASDAQ:SLN) Receives $57.20 Average PT from Brokerages

Shares of Silence Therapeutics plc (NASDAQ:SLN) have been assigned an average recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the stock in the last year is $57.20.

A number of equities research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Monday, December 9th. Morgan Stanley reaffirmed an “overweight” rating and issued a $49.00 target price on shares of Silence Therapeutics in a research report on Tuesday, October 8th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $55.00 target price on shares of Silence Therapeutics in a research report on Tuesday, December 10th. Finally, William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th.

Silence Therapeutics Stock Performance

SLN stock opened at $5.99 on Wednesday. The firm has a market capitalization of $179.27 million, a price-to-earnings ratio of -3.82 and a beta of 1.08. The firm has a 50 day moving average price of $9.07 and a 200-day moving average price of $15.27. Silence Therapeutics has a 52-week low of $5.81 and a 52-week high of $27.72.

Hedge Funds Weigh In On Silence Therapeutics

Several hedge funds have recently added to or reduced their stakes in SLN. GAMMA Investing LLC grew its stake in Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after acquiring an additional 5,233 shares in the last quarter. Y Intercept Hong Kong Ltd grew its stake in Silence Therapeutics by 22.9% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock worth $383,000 after acquiring an additional 3,923 shares in the last quarter. Point72 Asset Management L.P. grew its stake in Silence Therapeutics by 219.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock worth $8,505,000 after acquiring an additional 321,300 shares in the last quarter. Parkman Healthcare Partners LLC grew its stake in Silence Therapeutics by 71.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock worth $9,051,000 after acquiring an additional 208,029 shares in the last quarter. Finally, Ikarian Capital LLC grew its stake in Silence Therapeutics by 15.9% in the 3rd quarter. Ikarian Capital LLC now owns 587,343 shares of the company’s stock worth $10,678,000 after acquiring an additional 80,678 shares in the last quarter. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.